VEGF-A and FLT-1 tumour gene expressions are of prognostic value in small cell lung cancer (SCLC) patients treated with first-line ACE chemotherapy

VEGF-A and FLT-1 tumour gene expressions are of prognostic value in small cell lung cancer (SCLC) patients treated with first-line ACE chemotherapy

Bibliographic Details
Main Authors:	Brueckl, WM, Wirtz, R, Dimmler, A, Brunner, T, Klein, P, Hahn, E, Ficker, J, Wiest, G
Format:	Journal article
Published:	2009

Similar Items

TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study
by: Papadopoulos Thomas, et al.
Published: (2007-08-01)

Development and Validation of a Simplified Prognostic Score in SCLC
by: Elodie Negre, MD, et al.
Published: (2020-03-01)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance
by: Jin Yujuan, et al.
Published: (2023-05-01)

Exploring the prognostic impact of differences in treatment strategies for SCLC with different histologies and prognostic factors for C-SCLC: A SEER population-based study
by: Jiaping Liu, et al.
Published: (2024-06-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
by: Kana Hashimoto, MD, et al.
Published: (2024-11-01)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
by: Zhang C, et al.
Published: (2021-10-01)

Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients
by: Lixia Ju, et al.
Published: (2021-06-01)

Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway
by: Cong Hou, et al.
Published: (2021-08-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC
by: Meng-Yu Chen, et al.
Published: (2022-06-01)

Potential immunologic and prognostic roles of CHRNA6 in SCLC and pan-cancer
by: Qingqing Zhao, et al.
Published: (2024-10-01)

DNA methylation regulates expression of <it>VEGF-R2 </it>(<it>KDR</it>) and <it>VEGF-R3 </it>(<it>FLT4</it>)
by: Quentmeier Hilmar, et al.
Published: (2012-01-01)

AN UNORTHODOX PRESENTATION OF SCLC
by: Ruchee Khanna
Published: (2018-10-01)

Validity test of small cell lung cancer (SCLC) graded prognostic assessment and proposal of a new index for patients with brain metastases from SCLC
by: Masaaki Yamamoto, et al.
Published: (2024-09-01)

Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions
by: Song PF, et al.
Published: (2020-11-01)

Chemotherapy for small cell lung cancer (SCLC): standards of care for first presentation and relapse
by: Graham Ross
Published: (2004-03-01)

New developments in immunotherapy for SCLC
by: Zhonglin Hao, et al.
Published: (2025-01-01)

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
by: Salomon Tendler, et al.
Published: (2020-01-01)

Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
by: Na Wang, et al.
Published: (2021-01-01)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
by: Tamara Castaño-Bonilla, et al.
Published: (2021-10-01)

VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology.
by: Taylor, R, et al.
Published: (2012)

Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma.
by: Ajiravudh Subarnbhesaj, et al.
Published: (2017-01-01)

Coregulation of Glucose Uptake and Vascular Endothelial Growth Factor (VEGF) in Two Small-Cell Lung Cancer (SCLC) Sublines In Vivo and In Vitro
by: Minna W.B. Pedersen, et al.
Published: (2001-01-01)

What's New in SCLC? A Review
by: Bryan Oronsky, et al.
Published: (2017-10-01)

Combined SCLC clinical and pathological aspects
by: Filiz Çimen, et al.
Published: (2022-06-01)

Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC
by: Zhang Tao, et al.
Published: (2022-12-01)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
by: Frank G. Rücker, et al.
Published: (2024-12-01)

Characterization of a new small cell lung cancer (SCLC) cell line STP54 derived from a metastatic bioptate of a combined type of SCLC with Non-SCLC component.
by: Joanna Domagała-Kulawik, et al.
Published: (2009-05-01)

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy
by: Kim Byoung-Gie, et al.
Published: (2008-10-01)

VEGF-R1/Flt-1 Receptor as a Characteristic of the Angiogenic Phenotype of Uveal Melanoma
by: V. G. Likhvantseva, et al.
Published: (2021-12-01)

The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy.
by: Yaling Zhai, et al.
Published: (2020-01-01)

Acute Pulmonary Actinomycosis Induced by Immunotherapy and Chemotherapy Used for SCLC Treatment: A Case Report and Literature Review
by: Kuang J, et al.
Published: (2023-12-01)

Precise prediction of the sensitivity of platinum chemotherapy in SCLC: Establishing and verifying the feasibility of a CT-based radiomics nomogram
by: Yanping Su, et al.
Published: (2023-03-01)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
by: Anifat A. Elegbede, MSc, MbChB, et al.
Published: (2021-12-01)

Assessment of targets of antibody drug conjugates in SCLC
by: Abhishek Ajay, et al.
Published: (2025-01-01)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
by: Carpentier J, et al.
Published: (2022-09-01)

Impact of Socioeconomic Factors on Overall Survival in SCLC
by: Logan Roof, MD, et al.
Published: (2022-07-01)

Apatinib as Salvage Therapy for Heavily Pretreated SCLC
by: Fangfang LI, et al.
Published: (2018-07-01)

Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy.
by: Ya-Ling Zhai, et al.
Published: (2014-01-01)

The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients
by: Yu-Qing Chen, et al.
Published: (2023-01-01)